Trial · NCT03747575
Results by group23
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 23
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change of Total Eczema Area and Severity Index (EASI) Score | Treatment | -51.47 | Standard Error 8.639 | Percentage | |
| Percent Change of Total Eczema Area and Severity Index (EASI) Score | Placebo | -58.24 | Standard Error 9.092 | Percentage | |
| Proportion of Participants Who Achieve Investigator's Global Assessment (IGA) Response of 0 or 1 | Treatment | 15.2 | Percentage | ||
| Proportion of Participants Who Achieve Investigator's Global Assessment (IGA) Response of 0 or 1 | Placebo | 6.3 | Percentage | ||
| Proportion of Participants Who Achieve >/=75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) Score | Treatment | 27.3 | Percentage | ||
| Proportion of Participants Who Achieve >/=75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) Score | Placebo | 18.8 | Percentage | ||
| Percent Change in Pruritus as Assessed by a Numeric Rating Scale (NRS) | Treatment | -31.22 | Standard Error 7.376 | Percentage | |
| Percent Change in Pruritus as Assessed by a Numeric Rating Scale (NRS) | Placebo | -39.43 | Standard Error 7.839 | Percentage | |
| Percent Change in Body Surface Area (BSA) With Atopic Dermatitis (AD) Involvement | Treatment | -42.23 | Standard Error 8.637 | Percentage | |
| Percent Change in Body Surface Area (BSA) With Atopic Dermatitis (AD) Involvement | Placebo | -38.87 | Standard Error 9.134 | Percentage | |
| Percent Change in Disease Severity as Assessed by SCORing Atopic Dermatitis (SCORAD) | Treatment | -35.45 | Standard Error 6.837 | Percentage | |
| Percent Change in Disease Severity as Assessed by SCORing Atopic Dermatitis (SCORAD) | Placebo | -39.50 | Standard Error 7.202 | Percentage | |
| Percentage of Participants With Adverse Events (AE) | Treatment | 14 | Participants | ||
| Percentage of Participants With Adverse Events (AE) | Placebo | 18 | Participants | ||
| Serum Concentrations of MSTT1041A | Treatment | Day 1 Visit 2/prior to infusion | NA | Geometric Coefficient of Variation NA | ug/mL |
| Serum Concentrations of MSTT1041A | Treatment | Week 1 Visit 3/prior to infusion | 42.6 | Geometric Coefficient of Variation 34.4 | ug/mL |
| Serum Concentrations of MSTT1041A | Treatment | Week 4 Visit 5/prior to infusion | 37.6 | Geometric Coefficient of Variation 52.5 | ug/mL |
| Serum Concentrations of MSTT1041A | Treatment | Week 8 Visit 7/prior to infusion | 36.6 | Geometric Coefficient of Variation 54.5 | ug/mL |
| Serum Concentrations of MSTT1041A | Treatment | Week 12 Visit 9/prior to infusion | 40.1 | Geometric Coefficient of Variation 60.5 | ug/mL |
| Serum Concentrations of MSTT1041A | Treatment | Week 16 Visit 11 | 38.2 | Geometric Coefficient of Variation 76.0 | ug/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03747575/results